𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial

Book ID
117277383
Publisher
The Lancet
Year
2001
Tongue
English
Weight
366 KB
Volume
357
Category
Article
ISSN
0140-6736

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The Early Glycoprotein IIb/IIIa Inhibiti
The Early Glycoprotein IIb/IIIa Inhibition in Non–ST-Segment Elevation Acute Coronary Syndrome (EARLY ACS) trial: A randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non–ST-segment elevation acute coronary syndrome—Study design and rationale
✍ Robert P. Giugliano; L. Kristin Newby; Robert A. Harrington; C. Michael Gibson; 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 148 KB
The Efficacy and Safety of Prasugrel Wit
The Efficacy and Safety of Prasugrel With and Without a Glycoprotein IIb/IIIa Inhibitor in Patients With Acute Coronary Syndromes Undergoing Percutaneous Intervention: A TRITON–TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis In Myocardial Infarction 38) Analysis
✍ Michelle O'Donoghue; Elliott M. Antman; Eugene Braunwald; Sabina A. Murphy; P. G 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 480 KB